Showing results (2401-2410 of 2,456) with videos related to

Sort By:
Pageof 246
Gastroenterology|February 3, 2005
Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutantShui Ping Tu, Jian Tao Cui, Peter Liston, et al.
Neurology|January 26, 2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dGS M Hersch, S Gevorkian, K Marder, et al.
Science (New York, N.Y.)|December 12, 2024
An injury-induced mesenchymal-epithelial cell niche coordinates regenerative responses in the lungDakota L Jones, Michael P Morley, Xinyuan Li, et al.
American Journal of Respiratory and Critical Care Medicine|April 12, 2019
XBP1S Regulates MUC5B in a Promoter Variant-Dependent Pathway in Idiopathic Pulmonary Fibrosis Airway EpitheliaGang Chen, Carla M P Ribeiro, Ling Sun, et al.
Science Translational Medicine|January 31, 2024
TGF-βR2 signaling coordinates pulmonary vascular repair after viral injury in mice and human tissueGan Zhao, Lulu Xue, Aaron I Weiner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2022
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)Sai-Hong Ignatius Ou, Makoto Nishio, Myung-Ju Ahn, et al.
Nature Communications|November 7, 2020
mTORC1 activation in lung mesenchyme drives sex- and age-dependent pulmonary structure and function declineKseniya Obraztsova, Maria C Basil, Ryan Rue, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2021
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L TrialD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Nature|March 25, 2011
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onsetCraig J Ceol, Yariv Houvras, Judit Jane-Valbuena, et al.
Pageof 246